Decreased Antibody Response After Severe Acute Respiratory Syndrome Coronavirus 2 Vaccination in Patients With Down Syndrome 

 : The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks...

Descripción completa

Detalles Bibliográficos
Autores principales: Streng, Bianca M M, Bont, Marin, Delemarre, Eveline M, Binnendijk, Rob S, Smit, Gaby, den Hartog, Gerco, Coppus, Antonia M W, de Vries, Esther, Weijerman, Michel E, Lamberts, Regina, de Graaf, Gert, van der Klis, Fiona R, Vidarsson, Gestur, Rave, Neele, Bont, Louis J, Wildenbeest, Joanne G
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Oxford University Press 2022
Materias:
Brief Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9278229/
https://www.ncbi.nlm.nih.gov/pubmed/35748853
http://dx.doi.org/10.1093/infdis/jiac235
Descripción
Sumario: : The risk of a severe course of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) infection in adults with Down syndrome is increased, resulting in an up to 10-fold increase in mortality, in particular in those >40 years of age. After primary SARS-CoV-2 vaccination, the higher risks remain. In this prospective observational cohort study, SARS-CoV-2 spike S1–specific antibody responses after routine SARS-CoV-2 vaccination (BNT162b2, messenger RNA [mRNA]–1273, or ChAdOx1) in adults with Down syndrome and healthy controls were compared. Adults with Down syndrome showed lower antibody concentrations after 2 mRNA vaccinations or after 2 ChAdOx1 vaccinations. After 2 mRNA vaccinations, lower antibody concentrations were seen with increasing age. CLINICAL TRIALS REGISTRATION: NCT05145348.

Ejemplares similares